Involvement of oxidative species in cyclosporine-mediated cholestasis

Bernard Nsengimana, Edozie Samuel Okpara, Wanqing Hou, Chuyun Yan and Shuxin Han*

Department of Hepatobiliary Surgery, Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China

Cyclosporine is an established medication for the prevention of transplant rejection. However, adverse consequences such as nephrotoxicity, hepatotoxicity, and cholestasis have been associated with prolonged usage. In cyclosporine-induced obstructive and chronic cholestasis, for example, the overproduction of oxidative stress is significantly increased. Additionally, cyclosporine exerts adverse effects on liver function and redox balance responses in treated rats, as evidenced by its increasing levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin while also decreasing the levels of glutathione and NADPH. Cyclosporine binds to cyclophilin to produce its therapeutic effects, and the resulting complex inhibits calcineurin, causing calcium to accumulate in the mitochondria. Accumulating calcium with concomitant mitochondrial abnormalities induces oxidative stress, perturbation in ATP balance, and failure of calcium pumps. Also, cyclosporine-induced phagocyte oxidative stress generation via the interaction of phagocytes with Toll-like receptor-4 has been studied. The adverse effect of cyclosporine may be amplified by the release of mitochondrial DNA, mediated by oxidative stress-induced mitochondrial damage. Given the uncertainty surrounding the mechanism of cyclosporine-induced oxidative stress in cholestasis, we aim to illuminate the involvement of oxidative stress in cyclosporine-mediated cholestasis and also explore possible strategic interventions that may be applied in the future.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BDL, bile duct ligation; CRS, Cambridge Reference Sequence; ECSIT, Evolutionarily Conserved Signaling Intermediate in Toll pathway; GRP75, chaperone Glucose-Regulated Protein 75; GO, gene ontology; IP3R, inositol 1,4,5-triphosphate receptor; KEGG, Kyoto Encyclopedia of Genes and Genomes; mTORC1, mammalian target of rapamycin complex 1; MAM, Mitochondria-associated membrane; MCJ, Methylation-Controlled J-protein; MCU, Mitochondrial calcium unidirectional transporter; MPTP, Mitochondrial permeability transition pore; mtDNA, mitochondrial DNA; mtSSB, mitochondrial single-stranded DNA-binding protein; p-ERK, p-Extracellular Signal-Regulated Kinase; POLG, Mitochondrial DNA Polymerase G; PSIC, prolonged severe intrahepatic cholestasis; ROS, reactive oxygen species; TFAM, Mitochondria Transfer Factor A; TRAF-6, Tumor necrosis factor-associated factor-6.
Introduction

Cholestasis is a liver disease that causes a reduction or blockade in the flow of bile from the liver to the duodenum. Cholestasis can be intrahepatic or extrahepatic, with metabolic alterations, hepatitis, infection, and adverse drug reactions being the main causes of intrahepatic cholestasis and gallstones, cysts, and tumors being the main mechanical obstructions that lead to extrahepatic cholestasis. Because hydrophobic bile acids are harmful to hepatocytes and cholangiocytes, obstruction of bile flow causes retention of bile acids in the liver, resulting in liver damage (Nguyen et al., 2014; Visentin et al., 2018).

Individuals with prolonged severe intrahepatic cholestasis (PSIC) have a higher mortality risk (44%) than patients without PSIC (20%) after orthotopic liver transplantation (Funai et al., 2006). Cyclosporine, a potential immunosuppressant drug used in organ transplantation, can mediate the induction of the cholestasis (Bluhm et al., 1992). By inducing liver damage, cyclosporine inhibits vesicle intrahepatic transporters and also competes with ATP-driven transporters (Kolaric et al., 2019). Notably, 50% of patients develop cholestasis following a liver transplant, and 12% of cholestatic patients experience cyclosporine toxicity (Pecorella et al., 1990). Cyclosporine-induced cholestasis can subsequently exaggerate the liver damage and may require retransplantation. The impact of immunosuppressive drugs (cyclosporine and tacrolimus) in post-transplant patients has been shown to induce hepatotoxicity and cholestasis (Taniai et al., 2008). Furthermore, cyclosporine induces cholestasis in animals by decreasing bile flow and bile salt output while also elevating bile cholesterol levels, a significant risk factor for gallstone formation (Chan and Shaffer, 1997). Another study on an isolated perfused rat liver indicates that at 150 mg/L concentration, cyclosporine severely inhibits bile flow and begins to induce a cholestasis (Deters et al., 1997). Moreover, as seen in HepaRG cells, higher cyclosporine concentrations (≥50 μM) are associated with irreversible alterations in efflux and uptake activities, which ultimately resulted in the constriction of bile canaliculi and disorganization of the pericanalicular F-actin microfilaments (Sharanek et al., 2014). Although cyclosporine modulates bile acids flow, most studies are being carried out on isolated perfused rat liver with a supratherapeutic concentration of cyclosporine. Future studies could document the impact of cyclosporine on bile acids based on in vivo studies. Essentially, the effectiveness of organ transplantation has been considerably influenced by the use of cyclosporine to prevent allograft rejection. However, this outstanding accomplishment has certain unfavorable consequences, such as hypertension, nephrotoxicity, and liver toxicity (Rezzani, 2004). Importantly, several distinct processes, such as inflammatory reactions, programmed cell death, autophagy, and reactive oxygen species (ROS), are involved in the cyclosporine-induced nephrotoxicity (Lai et al., 2017). Palmero et al. (2001) show that cyclosporine-treated rats exhibit high levels of oxidized glutathione (GSSH) and oxidative stress, reduced superoxide dismutase activity, reduced glutathione (GSH) levels, and induction of cholestatic features in treated rats. Thus, understanding the potential mechanism(s) underlying cyclosporine-induced hepatotoxicity and whether or not the overproduction of oxidative species is an integral driving factor is still a fascinating subject, to this review seeks to partly illuminate.

According to a previous study, the liver function of cyclosporine-treated rats was also reduced with a corollary increase in blood levels of AST, ALT, and bilirubin (Korolczuk et al., 2016). Treated animals showed low levels of GSH (3.3 nmol/g vs. 6.65 nmol/g) and high levels of GSSG (1.33 nmol/g vs 0.38 nmol/g) compared with the control. Unsurprisingly, the ratio of NADP/NADPH was found to be higher in treated rats than in the control (3.48 vs. 0.72), which underlines the role of oxidative stress as a key factor in the molecular etiology of cyclosporine-induced liver damage (Korolczuk et al., 2016). In addition, the effect of cyclosporine on cholestasis has been studied in 55 patients who underwent a kidney transplant and were treated with cyclosporine. Findings show that total serum biliary salts, total bilirubin, alkaline phosphatase, and biliary lithiasis are increased in transplant patients compared with the control group (Soresi et al., 1995).

In obstructive cholestasis, chronic cholestasis, and other hepatopathies, the establishment of oxidative stress is significantly increased (Copple et al., 2010). Wolf et al. demonstrated that treatment of rat hepatocytes in a dose-dependent manner generated large amounts of free reactive species while also attenuating the levels of glutathione and the antioxidant ascorbic acid (Wolf et al., 1997). After receiving cyclosporine treatment, reactive species, redox imbalance, and mitochondrial DNA damage, significantly increased in rat hepatocytes (Korolczuk et al., 2016). Concerning glutathione levels, rats receiving oral treatment with cyclosporine experienced decreases in the mRNA expression levels of glutathione synthesizing enzyme (gamma glutamylcysteine light chain and heavy chain), which in turn affected the bile flow (Bramow et al., 2001). These findings further elucidate the potential role of oxidative stress, as well as GSH depletion, as driving mechanisms in the development of the cyclosporine-induced cholestasis (Moran et al., 1998; Vickers et al., 2017). Although glutathione is regarded as the “super” cofactor of
detoxifying enzymes and central antioxidants against oxygen species its role in cyclosporine-mediated cholestasis is still not fully understood. Determining how reactive species are involved and whether glutathione may have a protective impact in cyclosporine-induced cholestasis is the central aim of the current review.

**Cyclosporine: A potent inducer of oxidative species**

Upon its identification in the fungus *Tolyphostium inflatum* by the Swiss pharmaceutical company Sandoz Ltd., in 1971, cyclosporine was regarded as a narrow-spectrum antibiotic and antifungal agent with very constrained clinical applications. However, following the establishment of its immunosuppressive properties on T-lymphocytes, cyclosporine is now approved for use in autoimmune diseases (rheumatoid arthritis, psoriasis, Crohn’s disease, and keratoconjunctivitis) and has also significantly benefited organ transplantation since 1983 (Fattizzo et al., 2022). Despite cyclosporine’s usefulness in limiting organ transplant rejection, its use has been associated with some negative side effects, such as nephrotoxicity, neurotoxicity, and hepatotoxicity. Hepatotoxicity is characterized by symptoms such as jaundice, weariness, loss of appetite, and weight loss (Yalcin et al., 2021). Also, hepatotoxicity due to cyclosporine use has been associated with increased blood levels of bilirubin, lactate dehydrogenase, alanine aminotransferase, and alkaline phosphatase. Consequently, liver cells begin to exhibit vacuolar degeneration, turbidity, hypertrophy, apoptosis, and nuclear deterioration in the early stages of cyclosporine-induced hepatotoxicity. Moreover, these characteristics are linked to central lobule structural degradation, loss of cord-like structure, and lymphocyte and neutrophil infiltration (Patocka et al., 2021). Indeed, variability in serum levels has been identified as a contributory factor in cyclosporine-induced toxicity, and significant cyclosporine variability has also been linked to a high likelihood of allograft recurrent rejection (Flippin et al., 2000).

Importantly, cyclosporine-induced hepatotoxicity is a complex process that includes elevated intracellular calcium levels, malfunctioning mitochondria, and the generation of free radicals in the liver. Although the high dose (15 mg/kg) was used to indicate the effect of cyclosporine treated rats, rather than the actual dose used for humans (2.5 mg/kg), results demonstrate that cyclosporine medication can harm liver function and cause oxidative stress and redox imbalances in rat hepatocytes (Korolczuk et al., 2016). These findings reveal that prolonged usage of cyclosporine may culminate in impaired redox stability, thereby, causing cholestasis. Additionally, findings from the same study provide additional evidence that the major driving mechanisms in cyclosporine-induced hepatotoxicity are mitochondrial damage and oxidative stress (Korolczuk et al., 2016). Notably, the buildup of ROS caused by cyclosporine-mediated liver injury increases hydrogen peroxide levels and decreases superoxide dismutase activity (Andres and Cascales, 2002). Furthermore, the induction of calcium accumulation in the mitochondria due to cyclosporine treatment has also been identified as a toxic mechanism, as mitochondrial calcium accumulation disrupts ATP synthesis and results in the failure of the membrane calcium pump (Salducci et al., 1996).

**The mechanism by which cyclosporine induces oxygen species**

As a potent immunosuppressant, the major therapeutic effect of cyclosporine is the suppression of T-cell activity. T-cell receptors activate calcineurin by increasing intracellular calcium through calmodulin to elicit the T-cell response. The nuclear factor of activated T cells (NFAT) is then released from the cytosol by calcineurin, allowing for the entrance of NFAT into the nucleus, where it transactivates the expression of interleukin-2 and other cytokines (Fellman et al., 2019; Kitamura et al., 2020). Importantly, by attaching to the cytosolic protein cyclophilin D, cyclosporine stops this process. The cyclosporine-cyclophilin D complex then inhibits the action of the calcineurin enzyme, which in turn stops the generation of cytokines (Ke and Huai, 2004). Recent evidence from a yeast study reveals that a reduction in cytosolic calcium following the inhibition of the calcium/calcineurin pathway is associated with an increased level of ROS (Li et al., 2021). In a mammalian cell study, cyclosporine as a calcineurin inhibitor, promotes ROS formation, redox imbalance, and mitochondrial damage to induce hepatotoxicity (Korolczuk et al., 2016).

Interestingly, how cyclosporine contributes to hepatotoxicity caused by ROS is still a subject of open debate. ROS and NADPH oxidase-2 are produced in higher quantities in mice with calcineurin alpha knockdown, and cyclosporine-treated mice also exhibit similar outcomes (Cheriyan et al., 2021). However, cyclosporine can cause mitochondrial ROS accumulation without the involvement of the calcineurin (Zhou and Ryecom, 2014). By stimulating the NF-kB and toll-like receptor-4 (TLR4) pathways, in vitro cultures of murine primary cells study show that cyclosporine alone can sufficiently enhance the ROS generation (Rodrigues-Diez et al., 2016). Additionally, ROS are produced when TLR1, TLR2, and TLR4 stimulate the translocation of tumor necrosis factor receptor-associated factor 6 (TRAF6) into the mitochondria, promoting the degradation of the evolutionarily conserved signaling intermediate in the toll (ECSIT) protein (West et al., 2011).
Although hepatocytes isolated from cyclophilin D knockdown resist calcium overload and oxidative stress-induced cell death (Baines et al., 2005) and cyclosporine inhibits oxidation rates by hindering mitochondrial calcium efflux (Fournier et al., 1987), mitochondrial permeability transition pore (MPTP) can be mediated by other factors, including calcium, ROS, and lipid pores, allowing for MPTP-stimulated generation of ROS and induction of caspase-3 activity, which ultimately results in cell damage (Mironova and Pavlov, 2021; Skinner et al., 2021). The evidence further shows that cyclosporine can induce toxicity and this is dependent on the concentration used by mediating mitochondrial alterations (Jung and Pergande, 1985). Moreover, glycocholate increases the production of ROS in the mitochondria of human hepatocytes, a process essential for the induction of MPTP in a dose-dependent manner (Sokol et al., 2005). Notably, an interaction between cyclosporine and cyclophilin D has been linked to mitochondrial dysfunction and ROS generation (Klawitter et al., 2019). Hence, in wild-type mice treated with cyclosporine but not in cyclophilin D mutant animals, oxidative stress and 8-isoprostane levels are increased (Klawitter et al., 2019). To evaluate the involvement of MPTP in cholestasis, prior work in a mouse model showed that casein can enter the mitochondria following bile duct ligation (BDL), demonstrating the pathogenic role of MPTP in the cholestasis (Rehman et al., 2008). Despite the evidence demonstrating cyclosporine as a potent inhibitor of calcium-dependent MPTP in rat liver (Broekemeier et al., 1989), cyclosporine may also compromise the function of mitochondria and cause reactive species generation through a couple of other distinct routes (Figure 1).

**Mitochondrial dysfunction and oxidative species**

Cholestasis is characterized by the induction of oxidative stress and a dysfunctional mitochondrial architecture (Vinken, 2015). In contrast to untreated cholestatic animals, rats treated with edaravone following BDL showed elevated levels of ROS, oxidized glutathione, mitochondrial depolarization and permeability, reduced dehydrogenase activity, and fibrotic lesions (Mohammad Mehdi et al., 2021).

Patients with cholestatic disease frequently present increased expression of mitochondrial methylation-controlled J-protein (MCJ), which inhibits electron transport chain complex I. For this reason, bile acid-
induced mitochondrial ROS upregulation is scarce in MCJ-knockout mice (Iruzubieta et al., 2021). Rats subjected to BDL showed a decrease in mitochondrial biogenesis transcriptional regulators, such as liver peroxisome proliferator-activated receptor gamma coactivator-1alpha and mitochondrial transcription factor A, which demonstrates the role of mitochondrial dysfunction in cholestasis. Moreover, mitochondrial DNA (mtDNA) copies are also decreased to the lowest levels after 72 h of BDL (Tiao et al., 2009). Damage to the mitochondria can increase the severity of the disease by generating ROS, which then causes an accumulation of cytotoxic chemicals and ATP depletion (Heidari and Niknahad, 2019). The findings further demonstrate that the mitochondrial bioenergetics of cholestatic individuals are altered by varying bile acid concentrations (Rolo et al., 2000).

It is well known that mitochondria in the majority of cells are the primary producers of reactive species. The respiratory chain I and III complex and the pathway for the oxidation of fatty acids in mitochondria are the main sources of ROS in these organelles. Importantly, glutathione peroxidase and manganese superoxide dismutase in the mitochondria normally prevent the buildup of the ROS (Garcia-Ruiz and Fernandez-Checa, 2018). However, a high level of ROS can result in mtDNA depletion as well as damage to mitochondrial elements, including cardiolipin and other proteins required for the efficient functioning of the mitochondrial respiratory chain. ROS has a significant impact on mtDNA, and mtDNA abnormalities, in turn, result in mitochondrial dysfunction. Numerous studies have demonstrated evidence of oxidative stress-induced mitochondrial abnormalities involved in cholestasis and a potential mechanism based on the altered mtDNA copy number and imbalance of oxidants versus antioxidants in the mitochondria (Iruzubieta et al., 2021).

The Cambridge reference sequence (CRS) is the first full sequence of human mitochondrial DNA and was released in 1981. Led by Fred Sanger, the CRS project, which involved the sequencing of mtDNA from women of European heritage in the 1970s, results in greater insights into the evolution of human mitochondrial DNA (Iruzubieta et al., 2021). In sum, the integrity of mitochondria is critically important for maintaining mitochondrial bioenergetics, which is based on interrupting mtDNA activity. The drugs can induce mitochondrial toxicity by inhibiting mtDNA replication, translation, and/or methylation, as summarized in Table 1 (Le Guillou et al., 2018; Fromenty, 2020). Hence, mtDNA mitochondriotoxicity is expected to be a potentially ‘hot’ research direction for drug-induced liver toxicity. To the best of our knowledge, there is currently no record of any research that has examined the effects of cyclosporine on mtDNA mitochondriotoxicity-induced liver injury; however, only two studies have examined its effects on lung injury in the context of inflammation. According to the first study, cyclosporine inhibits inflammatory responses and mtDNA in the treated group after 15 min (Xiao et al., 2018). The second study indicates that mtDNA can act as a damage-associated molecular marker in lung injury. Only after the administration of cyclosporine for 15 min was a dose-dependent reduction in mtDNA and inflammatory responses observed (Liu et al., 2019). In sum, the integrity of mitochondria is

Importantly, to start the mitochondrial functional deficiency, mtDNA copies must fall below 20%-40% of the basal line. Cholestatic patients exhibit a high level of mitochondrial 8-hydroxydeoxyguanosine and deficient mtDNA characteristics, such as copy number, transcript level, and nucleoid structure, which are used to determine the alteration of mtDNA copies during cholestatic liver injury (Xu et al., 2012). The impact of mitochondrial failure on several biological processes, such as inflammatory stress, metabolic disorders, oxidative stress, and fibrosis, has been intensively studied as being related to cholestasis. Notably, cholestasis can become more severe when there are both mitochondrial abnormalities and mtDNA depletion or deletion (Arduini et al., 2012). The aforementioned data indicate that oxidative stress plays a significant role in mitochondrial dysfunction and hepatocyte damage. A recent study showed that oxidative phosphorylation-produced ROS can cause mtDNA damage (Nissanka and Moraes, 2018). Additionally, numerous diseases are linked to oxidative stress-induced mtDNA damage (Huang et al., 2020). Similarly, a mouse model study showed that a reduction in mitochondrial DNA polymerase g (POLG) is linked to higher levels of mutations and more apoptotic markers relative to the control group with intact POLG expression levels (Lee and Wei, 1997; Kujoth et al., 2005). In addition, patients with liver diseases have reduced expression levels of mtDNA-encoded proteins (Santamaria et al., 2003). Liver damage is promoted by a decrease in mtDNA in liver cells, which obstructs mitochondrial function (Demelli et al., 2002).

As mtDNA research is still in its infancy, few studies have yet shown that the impact of several drugs on hepatotoxicity is based on interrupting mtDNA activity. The drugs can induce mitochondrial toxicity by inhibiting mtDNA replication, translation, and/or methylation, as summarized in Table 1 (Le Guillou et al., 2018; Fromenty, 2020).
TABLE 1 Effect of some drugs on mtDNA.

| Drug              | Mode of action                                                                 | Effect to mtDNA                                                                 | References                                |
|-------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|-------------------------------------------|
| 4-quinolone       | A fluoroquinolone which inhibits bacterial DNA topoisomerase during DNA replication | Decreases mtDNA content and reduces the mitochondrial respiration              | Lawrence et al. (1993)                    |
| Fialuridine       | 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodouracil that used to treat chronic hepatitis B | Suppresses DNA polymerase gamma and promotes mtDNA reduction                  | Lewis et al. (1996)                       |
| Ganciclovir       | 9-(1,3-dihydroxy-2-propanoylmethyl) guanine which inhibits viral DNA replication by targeting ganciclovir-5-triphosphate | mtDNA depletion and mitochondrial impairment                                     | Herranz et al. (2003)                     |
| Tacrine           | It induced a reversible inhibition of acetylcholinesterase                      | Reduces the integration of [3H] thymidine into mtDNA, reduces mtDNA, and partly unwound supercoiled mtDNA into circular mtDNA | Mansouri et al. (2003)                     |
| Tamoxifen         | An anti-estrogenic drug that competes with 17β-estradiol at the receptor site and to block the activity of E2 in breast cancer | It inhibits topoisomerases and leads to mtDNA depletion                        | Larosche et al. (2007)                    |
| Linezolid         | It inhibits bacterial protein synthesis by preventing the formation of a functional 70S initiation complex | It decreases the mtDNA-encoded peptide translation                            | De Vriese et al. (2006)                   |
| Tetracycline      | Inhibits the protein synthesis by binding to aminocyl tRNA to the A-site of the ribosome | It suppresses the mitochondrial translation                                      | Skrtic et al. (2011)                      |
| Valproic Acid     | An antiepileptic drug which binds on gamma aminobutyric acid                     | It promotes mtDNA methylation                                                  | Wolters et al. (2017)                     |

crucial for cells, and the effects of medications on mitochondria as well as mtDNA are therefore used by pharmaceutical companies to evaluate the safety of drugs. It is also known that mitochondria play a tight regulatory role in calcium buffering. The relationship between mitochondria-mediated calcium homeostasis and oxidative stress-induced cholestasis remains to be further explored.

According to the aforementioned studies, it is clear that mitochondrial abnormalities contribute to the onset of cholestasis, albeit the prevailing lack of clarity on the effect of cyclosporine on mitochondrial activity in cholestasis. Findings also reveal that the liver function examination of a rat treated with cyclosporine exhibits significant changes in oxidative stress markers, a considerable rise in ALT, AST, and bilirubin levels in serum, mononuclear cell infiltration, and obvious mitochondrial damage (Korolczuk et al., 2016; Dada et al., 2021). Depending on the dosage used, cyclosporine can also protect mitochondria by suppressing MPTP (Almofti et al., 2003; Hicks et al., 2009). Ions with sizes less than 1,500 Da are known to enter the MPTP. The enlargement and breakdown of the mitochondrial membrane potential are linked to this buildup of chemicals inside the mitochondria. To prevent hepatocyte necrosis, cyclosporine and trifluoperazine block the pores (Broekemeier et al., 1989; Imberti et al., 1993). A recent study, however, found that cyclosporine can, in an age-dependent manner, extend the time needed to induce MPTP. Furthermore, MPTP can be induced by bile acids, particularly glycochenodeoxycholate, which is one of the bile salts whose concentration rises by more than 20-fold during cholestasis (Yerushalmi et al., 2001). Interestingly, the combination of trifluoperazine and cyclosporine prevents the opening of the mitochondrial permeability pore caused by the glycochenodeoxycholate (Gores et al., 1998). Taken together, apart from being an inducer of oxidative species, cyclosporine can inhibit cytosolic calcium, and the evidence further shows that aberrant cytosolic calcium and high accumulation of calcium in mitochondria are also associated with ROS formation. However, mitochondrial defects are associated with cholestasis, and the combination of cyclosporine and trifluoperazine can suppress MPTP. Future studies could clarify to what extent cyclosporine can induce mitochondrial damage or protect the MPTP.

Endoplasmic reticulum-calcium signaling-mitochondrial damage crosstalk

Calcium is a multipurpose second messenger that regulates a wide range of physiological pathways, including lipid and glucose metabolism, cell replication, cell death, and bile secretion (Amaya and Nathanson, 2013). Liver damage may correlate with the dysregulation of the calcium homeostasis (Oliva-Vilarnau et al., 2018). Although it is well known that calcium is mostly deposited in the endoplasmic reticulum, calcium signaling controls mitochondrial function, particularly via the regulation of Krebs cycle enzymes; mitochondria, also controls the calcium dynamics (Bravo-Sagua et al., 2017). Depending on the inositol 1,4,5-triphosphate receptor (IP3R) and the chaperone protein glucose-regulated protein 75 (GRP75), calcium could gain entrance into the mitochondria through a mitochondria-associated membrane (MAM), which then triggers the
opening of the mitochondrial calcium unidirectional transporter (MCU) (Wang et al., 2020). Furthermore, a sodium-calcium exchanger is used by liver cells to absorb 60% of the calcium (Bernstein and Santacana, 1985).

A more recent study confirmed that mtDNA can impact calcium signaling, stressing that cells with mtDNA depletion exhibit significantly reduced calcium signaling cascades (Sherer et al., 2000). In a similar study, mtDNA polymorphism analysis demonstrated that transmembricial cytoplasmic hybrid cells with 8701A/10398A are more closely related to the intracellular calcium dynamicity (Kazuno et al., 2006). However, another study showed that 25 µg/ml of ciprofloxacin can cause cells to lose 60% mtDNA content, which therefore results in a decreased mitochondrial membrane potential and mitochondria-mediated calcium buffering capacity. Incubation with ciprofloxacin for 4 and 11 days reduces the cellular calcium entry rate by 33% and 50%, respectively (Koziel et al., 2006).

**Calcium signaling and related biological processes**

Although our focus in the current review is on oxidative stress and cholestasis, we have also summarized the effect of calcium on related biological processes, especially the endoplasmic reticulum. According to a recent study, the opening of the sodium-calcium exchanger affects the hydrophobic bile acid activity (Zhu et al., 2016). Although calcium controls Krebs cycle enzymes in mitochondria, research suggests that sodium-calcium exchangers also control oxidative stress. Increased calcium input into mitochondria and production of ROS are observed when the expression of the sodium-calcium exchanger is knocked down in rats using siRNA (Zu et al., 2015). A similar phenomenon occurs in rabbit cardiomyocytes, where calcium entry via a sodium-calcium exchanger results in ROS and cardiac damage (Wagner et al., 2003). The study demonstrated that reconfiguration of MAM is linked to excessive calcium accumulation, decreased oxidative capacity, and increased oxygen reactive species in the mitochondria (Arruda et al., 2014).

Furthermore, cholestasis is characterized by the IP3R loss (Shibao et al., 2003). In cholestatic individuals, IP3R is inhibited by miRNA-506, which targets its 3′-UTR and blocks the calcium transmission (Ananthanarayanan et al., 2015). These findings demonstrate the involvement of calcium transporters in calcium-induced oxidative species and the aberrant expression of these transporters in cholestasis. Additionally, pretreatment phenylephrine hepatocytes exposed to a hazardous amount of menadione increase the quantity of calcium in the cytosol, demonstrating the relationship between oxidative stress and the calcium signaling (Nicotera et al., 1988). ROS can be produced by mitochondria in a variety of ways, including by accelerating metabolic reaction rates, causing the release of cytochrome c and MPTP, and by activating the calcium-calmodulin transmission (Peng and Jou, 2010). In addition, 10 mM H2O2 was employed to examine how oxidative species affected calcium signaling. The findings demonstrate that the dosage of H2O2 causes a rise in mitochondrial calcium while having no effect on the cytoplasmic calcium (Greene et al., 2002).

Importantly, the production of ROS is crucial to understanding the overall effect of ROS generation on endoplasmic reticulum stress. ROS generated due to the entry of calcium into the mitochondria, can induce endoplasmic reticulum stress under conditions of liver injury, especially drug-induced liver toxicity (Zeeshan et al., 2016). The overproduction of ROS compromises the functional integrity of the endoplasmic reticulum for calcium release, allowing for the induction of cholestasis. A fatal hypermetabolic reaction is linked to low expression of calsequestrin-1, a calcium-binding protein in the sarcoplasmic reticulum. In animals given the antioxidant N-acetylcysteine, calsequestrin-1 knockout reduced mitochondrial superoxide production while increasing glutathione levels in comparison to the control group (Michelucci et al., 2015). Importantly, the abnormal expression of calsequestrin-1 is linked to high levels of oxidative stress production and mitochondrial damage (Paolini et al., 2015). Furthermore, the inhibition of GRP75 reduces the buildup of calcium in the mitochondria and the production of ROS (Honrath et al., 2017).

MPTP impairment is promoted by aberrant mitochondrial calcium levels caused by naphthylisothiocyanate, a cholestasis-inducing agent (Reichen et al., 1985). Calcium deficiency causes cholestasis by increasing biliary permeability and canalicular dysfunction. Although mitochondria and the endoplasmic reticulum are linked to calcium homeostasis, endoplasmic calcium is not the inducer of the cholestasis (Farrell et al., 1990). However, biliary epithelial cells have higher levels of endoplasmic reticulum stress markers, which drive cell death (Sasaki et al., 2015). As oxidative stress can be controlled by the endoplasmic reticulum, tunicamycin, an endoplasmic reticulum stressor, also causes oxidative stress, elevated levels of AST and ALT, and liver cell damage due to lipid peroxidation and glutathione depletion. Curiously, therapy with 2% taurine reverses these effects (Kim et al., 2022). The link between endoplasmic reticulum stress and drug-induced cholestasis has also been demonstrated. The results show that liver injury precedes the generation of ROS caused by endoplasmic reticulum stress, which is an early event in drug toxicity-mediated cholestasis. Essentially, the activation of HSP27-PI3K-AKT decreases drug-induced endoplasmic reticulum stress as well as oxidative stress and also abrogates the liver damage (Burban et al., 2018).
Mechanisms of cyclosporine-induced cell injury

Induction of endoplasmic reticulum stress

Cyclosporine has been shown to mediate chronic nephrotoxicity. Results from the literature review show that cyclosporine produces endoplasmic reticulum stress, which results in protomyofibroblast formation and activation of transforming growth factor. Interestingly, salubrinal, which lessens endoplasmic reticulum stress, protects against phenotypic changes in epithelial cells (Pallet et al., 2008). Furthermore, cyclosporine increases endoplasmic reticulum stress by increasing GRP78 expression and stimulating the apoptosis (Liu et al., 2015). It is crucial to determine whether endoplasmic reticulum stress and oxidative stress are connected with cyclosporine use in cholestasis. In a concentration-dependent manner, cyclosporine has been shown to induce endoplasmic reticulum stress in HepaRG cell lines, which is followed by the generation of oxidative stress. These alterations are related to aberrant expression of the bile acid enzyme regulator and bile acid buildup in cells and culture media (Sharanek et al., 2014; Gijbels et al., 2020).

Contrastively, the findings show that, depending on the level of calcium, cyclosporine can protect hepatocytes against oxidative stress. Notably, cyclosporine protects cells treated with 0.8 mM t-butylhydroperoxide with 10 mM calcium, but this protection is ineffective at 2.5 mM calcium (Broekemeier et al., 1992). Furthermore, while infantile cholestasis caused by toxic bile acids results in liver damage and mortality, the role of calcium signaling in this pathophysiology is still unknown. Specifically, calcium-sensing receptors are elevated during infantile cholestasis, and their elevation enhances the activation of p-extracellular signal-regulated kinase (p-ERK) which in turn lessens the expression of apoptotic markers, lowers intracellular calcium, and also inhibits the development of oxidative stress (Qin et al., 2020). As summarized in Figure 2, cyclosporine can induce cell injury by mediating ROS generation due to interorganelle communication.

Reactive oxygen species involvement and the role of reduced glutathione

Glutathione is generated by the formation of a gamma peptide bond between glutamate and cysteine, allowing for the...
binding of glycine to the carboxyl group of glutamylcysteine. As an antioxidant, glutathione has been shown to not only protect cells from ROS, such as peroxidase and free radicals but it has also been shown to be the central positive regulator of the cell’s antioxidant systems (Forman et al., 2009). The biosynthesis of glutathione involves two stages, the first of which is catalyzed by glutamate-cysteine ligase/glutamate cysteine synthase and involves the conversion of L-glutamate and cysteine into gamma-glutamylcysteine a precursor of glutathione. In stage 2 of this process, C-terminal gamma-glutamylcysteine receives glycine from glutathione synthase, allowing for the generation of GSH. As a cofactor of glutathione peroxidase and as part of the liver detoxification and biotransformation processes, glutathione participates in a variety of cellular processes (Pastore et al., 2003). Glutathione reductase catalyzes the conversion of glutathione disulfide into its reduced state, a process requiring NADPH. GSH thereafter protects cells by neutralizing ROS and free radicals (Xiao and Loscalzo, 2020).

As part of their defense system, normal liver cells typically release minute amounts of ROS. Moreover, mitochondria could also be an intracellular source of ROS since complexes I and III are capable of releasing electrons. Importantly, hepatocytes have developed defenses to mitigate the detrimental buildup of ROS within the cell, and GSH-coordinated antioxidant systems, such as catalase, glutathione peroxidase, and superoxide dismutase, play essential roles in this regard (Cichoz-Lach and Michalak, 2014). Generally, hepatocytes maintain redox-active iron for protein localization and possess a layered defense mechanism against ROS, which includes the presence of glutathione in all cellular compartments and vitamin C (an antioxidant) in cell membranes (Akbay et al., 2019). However, as glutathione levels drop in the mitochondria, ROS buildup precipitates, eventually causing the opening of the MPTP and the subsequent release of pro-apoptotic factors, principally endonuclease G, into the nucleus, where they cause DNA fragmentation and ATP depletion (Imaizumi and Aniya, 2011).

ROS generated by inflammation can also cause liver injury in addition to cell death caused by mitochondrial malfunction. Typically, cholestasis induces the molecular patterns linked with damage that cause the activation of the complement cascade (Jaecke and Ramachandran, 2011). Cholestasis can also induce the activation of the TLR, which attracts neutrophil-like macrophages. ROS activation from phagocytic cells can be further aided by complement cascade activation and inflammatory response activation (Yang et al., 2019; Xiao and Loscalzo, 2020).

Mechanistically, to induce liver injury, a high concentration of ROS suppresses the effect of mammalian target of rapamycin complex 1 (mTORC1) by activating cytoplasmic ataxia telangiectasia mutated (ATM). ROS burst-induced peroxide enhances protein-1 activation, which then upregulates REDD1 and downregulates mTORC1. In addition, studies show that ROS regulates different cellular pathways, such as the AKT/mTOR, Notch, Wnt, and JAK-STAT pathways (Stacy Grieve, 2022). Similarly, ROS suppresses mTORC1 expression by upregulating AMPK. In addition, animal study shows that cyclosporine induces hepatic GSH depletion, while renal GSH remains unaffected (Jimenez et al., 2000). Interestingly, N-acetylcysteine, acting as an antioxidant, reinstates the mTORC1 activity (Zhang T. et al., 2019).

Conclusion and future perspectives

Allograft rejection is significantly reduced by the use of cyclosporine. However, as a result of extended exposure or high serum levels of cyclosporine, patients may develop side effects such as hepatotoxicity and cholestasis. Therefore, alternative ways to improve the clinical outcome of this outstanding drug are urgently needed. Importantly, cyclosporine-induced cellular damage occurs via different key mechanisms: induction of mitochondrial calcium accumulation (which results in mitochondrial abnormalities and disruption in ATP homeostasis); ROS generation; and the translocation of TRAF-6 into the nucleus (following the interaction of cyclosporine with TRAF-4), which causes TRAF-6-induced ECSIT breakdown and fosters the formation of oxidative species. To elicit their effect, ROS modulate several pathways, including mTORC1, AKT/mTOR, Notch, Wnt, and JAK-STAT. In this regard, the potential function of antioxidants, such as glutathione, vitamin C, and N-acetylcysteine, in attenuating cyclosporine-induced hepatotoxicity, particularly cholestasis, can be used as strategic support. In an animal model of the disease, the antioxidant resveratrol demonstrates a protective potential against hepatotoxicity by attenuating cyclosporine-induced ROS accumulation, decreasing advanced oxidation protein products as well as suppressing levels of thiobarbituric acid reactive substances (Bingul et al., 2021).

Exploration of the role of cyclosporine in liver damage and cholestasis, in particular, based on the drug’s toxic effects on mitochondria, including mtDNA depletion, mitochondria-peptide translation impairment, and mtDNA methylation, is indeed an intriguing research interest. Notably, while mtDNA release causes the interconnection of both oxidative stress and inflammatory response formation, the inflammatory response generated is intensified as mtDNA release continues unabated, eventually altering the functional integrity of the mitochondria. Moreover, mtDNA release is regarded as a damage-associated molecular pattern in the context of inflammation that can activate TLRs and trigger the production of interferon and cytokines, leading to cell injury (Zhang X. et al., 2019). On the other hand, ROS can promote the activation of transcription factors connected to inflammatory signaling pathways (Reuter
et al., 2010). Cell damage and chronic inflammation can be induced by the interaction between oxidative species and mitochondrial defect/mtDNA release. In addition, impaired protein translation is connected to drug-mediated mtDNA depletion. Therefore, a promising treatment strategy for liver damage and cholestasis could be a medication, especially those that increase serum levels of GSH that can improve oxidative pathways and also restore mitochondrial integrity.

It is worth noting that calcium signaling plays a vital role in the control of oxidative species in light of the aforementioned facts. Evidence also shows that endoplasmic reticulum-mitochondrial communication mediates the control of calcium signaling. By focusing on MAM and other calcium transporters, such as MCU, future studies can examine the usefulness of mitochondria-endoplasmic reticulum involvement in cholestasis. In addition, according to a recent study, more than 50% of cholestatic patients had low bone mineral density, and more than 50% of cholestatic patients had low vitamin D levels, which are important for calcium absorption (Samra et al., 2018). Interestingly, taking 25-hydroxyvitamin D3 orally can enhance calcium absorption (Rengoa et al., 1984). Therefore, it is crucial to compile more translational methods that may be applied in the future to improve calcium absorption and its effectiveness in cholestatic patients, as well as to effectively abrogate oxidative species and GSH plays an important role in this regard which has been observed to make integral contributions to the molecular mechanisms driving drug-induced toxicities.

By using different gene set collections such as Tox action, Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene ontology (GO) Biol process, findings show that cyclosporine affects several biological processes including apoptosis, DNA repair, oxidative phosphorylation, endoplasmic reticulum stress, and oxidative stress (Schmeits et al., 2015). Moreover, the aforementioned studies reveal that cyclosporine modulates bile acids secretion, and bile acids accumulation impairs mitochondria bioenergetics. However, antioxidant usage inhibits bile acids-induce MPTP, which reveals that bile acids can alter the mitochondria activity by inducing ROS production. Therefore, mitochondrial integrity could clinically be taken into account, especially in cholestatic patients.

Author contributions

BN prepared the manuscript. EO, WH, CY, and SH edited and revised the manuscript. SH supervised and validated the whole process of manuscript preparation.

Funding

This work is supported by the National Natural Science Foundation of China (Grant No. 32171167), Natural Science Foundation of Anhui Province, China (Grant No. 2108085MC89).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Abay, E., Erdem, B., Ural, A., Durukan, A. B., and Omur, M. A. (2019). Effects of N-acetyl cysteine, vitamin E and vitamin C on liver glutathione levels following amidarone treatment in rats. Kardiochir Torakochirurgia Pol. 16 (2), 88–92. doi:10.5114/ktp.2019.86361

Almofti, M. R., Ichikawa, T., Yamashita, K., Terada, H., and Shinohara, Y. (2003). Silver ion induces a cyclosporine a-insensitive permeability transition in rat liver mitochondria against cyclosporine A cytotoxicity in cultured rat hepatocytes. Biochem. Pharmacol. 64 (2), 267–276. doi:10.1016/s0006-2952(02)01112-7

Akbay, E., Erdem, B., Ural, A., Durukan, A. B., and Omur, M. A. (2019). Effects of N-acetyl cysteine, vitamin E and vitamin C on liver glutathione levels following amidarone treatment in rats. Kardiochir Torakochirurgia Pol. 16 (2), 88–92. doi:10.5114/ktp.2019.86361

Amaya, M. J., and Nathanson, M. H. (2013). Calcium signaling in the liver. Compr. Physiol. 3 (1), 515–539. doi:10.1002/cphy.c120013

Ananthanarayanan, M., Banales, J. M., Guerra, M. T., Spriet, C., Munoz-Garrido, P., Mitchell-Richards, K., et al. (2015). Post-translational regulation of the type III inositol 1, 4, 5-trisphosphate receptor by miRNA-506. J. Biol. Chem. 290 (1), 184–196. doi:10.1074/jbc.M114.587030

Andres, D., and Cascales, M. (2002). Novel mechanism of Vitamin E protection against cyclosporine A cytotoxicity in cultured rat hepatocytes. Biochem. Pharmacol. 64 (2), 267–276. doi:10.1016/s0006-2952(02)01112-7

Arruda, A. P., Pers, B. M., Parlakgul, G., Guney, E., Inouye, K., and Hotamisligil, G. S. (2014). Chronic enrichment of hepatic endoplasmic reticulum-mitochondria contact leads to mitochondrial dysfunction in obesity. Nat. Med. 20 (12), 1427–1435. doi:10.1038/nm.3735

Authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
et al. (2006). Linezolid-induced inhibition of mitochondrial protein synthesis. _Infect. Dis._ 18 (4), 727.

J. Complement. Integr. Med.

Bengoa, J. M., Sitrin, M. D., Meredith, S., Kelly, S. E., Shah, N., Baker, A. L., et al. (1984). Intestinal calcium absorption and vitamin D status in chronic cholestatic liver disease. _Hepatology_ 4 (2), 261–265. doi:10.1002/hep.184004215

Bernstein, J. and Santacana, G. (1985). The Na+Ca2+ exchange system of the liver cell. _Rev. Chem. Pathol. Pharmacol._ 47 (1), 3–34.

Bingul, I., Olgac, V., Bekpinar, S., and Uysal, M. (2021). The protective effect of resveratrol against cyclosporine A-induced oxidative stress and hepatotoxicity. _Arch. Physiol. Biochem._ 127 (6), 551–556. doi:10.1080/13813435.2019.1659826

Bluhm, R. E., Rodgers, W. H., Black, D. L., Wilkinson, G. R., and Branch, R. (1992). Cholestasis in transplant patients: what is the role of cyclosporin? _Aliment. Pharmacol. Ther._ 6 (2), 207–219. doi:10.1111/j.1365-2036.1992.tb0024x

Bramow, S., Ott, P., Thomsen Nielsen, F., Bangert, K., Tytgat, N., and Dalhoff, K. (2001). Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and ursodeoxycholic acid (Rapamycin). _Pharmacol. Toxicol._ 89 (3), 133–139. doi:10.1515/JPX.1997.0733.2001.d101-147

Bravo-Sagua, R., Parra, V., Lopez-Crisostio, C., Diaz, P., Quest, A. F., and Lavandero, S. (2017). Calcium transport and signaling in mitochondria. _Compr. Physiol._ 7 (2), 623–634. doi:10.1002/cphy.c160013

Broekemeer, K. M., Carpenter-Deyo, L., Reed, D. J., and Pfeiffer, D. R. (1992). Cyclosporin A protects hepatocytes subjected to high Ca2+ and oxidative stress. _FEBS Lett._ 304 (2-3), 192–196. doi:10.1002/1437-4038(19921623)304:2-3<192::AID-FEBS16>3.0.CO;2-T

Broekemeer, K. M., Dempsey, M. E., and Pfeiffer, D. R. (1989). Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in mitochondria. _J. Biol. Chem._ 264 (24), 7826–7830. doi:10.1074/jbc.264.24.7826

Burhan, A., Sharanek, A., Guguan-Guillouzo, C., and Guillouzo, A. (2018). Endoplasmic reticulum stress precedes oxidative stress in antibiotic-induced cholestasis and cytotoxicity in human hepatocytes. _Free Radi. Biol. Med._ 115, 166–178. doi:10.1016/j.freeradbiomed.2017.11.017

Chan, F. K., and Shaffer, E. A. (1997). Cholestatic effects of cyclosporine in the rat. _Transplantation_ 63 (11), 1574–1578. doi:10.1097/00007890-199709150-00006

Cherryan, A. M., Urre, A. C., Francis, C. E., King, K. N., Linck, V. A., Bai, Y., et al. (2021). Calciumineurin A-a suppressor drives nuclear factor-κB-mediated NADPH oxidase-2 upregulation. _Am. J. Physiol. Ren. Physiol._ 320 (5), F789–F790. doi:10.1152/ajprenal.00254.2020

Chicher-Lach, H., and Michalak, A. (2014). Oxidative stress as a crucial factor in liver diseases. _World J. Gastroenterol._ 20 (25), 8082–8091. doi:10.3748/wjg.v20.i25.8082

Coppell, B. L., Jaeschke, H., and Klaassen, C. D. (2010). Oxidative stress and the pathogenesis of cholestasis. _Semin. Liver Dis._ 30 (3), 192–204. doi:10.1055/s-0030-1253228

Dada, F. A., Oyelue, S. I., Adedipe, S. A., Babatola, L. J., and Adebayo, A. (2021). Evaluation of different almond (Terminalia catappa L.) extracts for potent inhibitor of the inner membrane permeability transition in liver. _Arch. Biochem. Biophys._ 634. doi:10.1002/cphy.c160013

Deters, M., Strubelt, O., and Younes, M. (1997). Reevaluation of cyclosporine A-mediated NADPH oxidase-2 upregulation. _Arch. Toxicol._ 94 (4), 1151–1172. doi:10.1007/s00204-020-02691-9

Dore, G. J., Miyoshi, H., Bodla, R., Aguilar, H. I., and Bronk, S. F. (1998). Induction of the mitochondrial permeability transition as a mechanism of liver injury during cholestasis: A potential role for mitochondrial proteasomes. _Biochem. Biophys. Acta._ 1366 (1-2), 167–175. doi:10.1016/s0006-3898(98)00111-x

Dore, G. J., Miyoshi, H., Bodla, R., Aguilar, H. I., and Bronk, S. F. (1998). Induction of the mitochondrial permeability transition as a mechanism of liver injury during cholestasis: A potential role for mitochondrial proteasomes. _Biochem. Biophys. Acta._ 1366 (1-2), 167–175. doi:10.1016/s0006-3898(98)00111-x

Greene, V., Cao, H., Schanne, F. A., and Bartelt, D. C. (2002). Oxidative stress-induced calcium signalling in Aspergillus nidulans. _Cell. Signal._ 14 (7), 433–443. doi:10.1016/s0898-6568(01)00266-2

Hersadri, R., and Nikradhah, H. (2019). The role and study of mitochondrial impairment and oxidative stress in cholestasis. _Methods Mol. Biol._ 1811, 117–132. doi:10.1007/978-1-4939-9420-5_8

Herraz, M., Beraza, N., Solano, A., Sangro, B., Montoya, J., Qian, C., et al. (2003). Liver failure caused by herpes simplex virus thymidine kinase plus ganciclovir therapy is associated with mitochondrial dysfunction and mitochondrial DNA depletion. _Hum. Gene Ther._ 14 (5), 463–472. doi:10.1089/hum.2003.12467225

Hicks, D., Lampe, A. K., Laval, S. H., Allamand, V., Jimenez-Mallebrera, V., Walter, M. C., et al. (2009). Cyclosporine A treatment for ulrich congenital muscular dystrophy: A cellular study of mitochondrial dysfunction and its rescue. _Brain_ 132 (1), 147–155. doi:10.1093/brain/awm289

Honrath, B., Metz, I., Bendridi, N., Reusset, J., Culmsee, C., and Dolga, A. M. (2017). Glucose-regulated protein 75 determines ER-mitochondrial coupling and sensitivity to oxidative stress in neuronal cells. _Cell Death Discov._ 3, 17076. doi:10.1038/cddiscovery.2017.76

Huang, Z., Chen, Y., and Zhang, Y. (2020). Mitochondrial reactive oxygen species cause major oxidative mitochondrial DNA damages and repair pathways. _J. Biosci._ 45, 84. doi:10.1007/s12038-020-00055-0

Izumiya, N., and Aniya, Y. (2011). The role of a membrane-bound glutathione transferase in the peroxynitrite-induced mitochondrial permeability transition pore: formation of a disulfide-linked protein complex. _Arch. Biochem. Biophys._ 516 (2), 160–172. doi:10.1016/j.abb.2011.10.012

Imberti, R., Nieminen, A. L., Herman, B., and Lemasters, J. J. (1993). Mitochondrial and glycolytic dysfunction in lethal injury to hepatocytes by t-butylhydroperoxide: Protection by fructose, cyclosporin A and tromethamine. _J. Pharmacol. Exp. Ther._ 265 (1), 392–400.

Irurzubeta, P., Gokkoetxea-Uasandizaga, N., Barber-Torres, L., Serrano-Macia, M., Fernandez-Ramos, D., Fernandez-Tussy, P., et al. (2021). Boosting mitochondria alleviates hepatic steatosis, insulin resistance, and liver injury in mice. _Am. J. Pathol._ 193 (2), 658–670. doi:10.1016/j.ajpath.2020.11.078

Jung, K., and Pergande, M. (1985). Influence of cyclosporin A on the respiration of isolated rat liver mitochondria. _FEMS Lett._ 183 (1), 167–169. doi:10.1016/0168-6444(85)80977-7

Kazuno, A. A., Munakata, K., Nagai, T., Shimozono, S., Tanaka, M., Yoneda, M., et al. (2006). Identification of mitochondrial DNA polymorphisms that alter
Saccharomyces cerevisiae signaling in regulating intracellular reactive oxygen species homeostasis in hepatoblasts. Somadossi, J.P., et al. (1996). Fialuridines and metabolites inhibit DNA mitochondrial matrix pH and intracellular calcium dynamics. Hepatology 7 (1), 86–92. doi:10.1016/j.hepat.2018.01.019

Kollaric, T. O., Nincevic, R., Smolic, R., Smolic, M., and Wu, G. Y. (2019). Mechanisms of hepatic cholestatic drug injury. J. Clin. Transl. Hepatol. 7 (1), 51–65. doi:10.1002/jcth.24051

Kai, G., Kujoth, G. C., Hiona, A., Pugh, T. D., Someya, S., Panzer, K., Wohlgemuth, S. E., and Kuoj, H., and Huai, Q. (2004). Crystal structures of cyclophilin and its partners. FEBS Lett. 572 (1), 86–92. doi:10.1016/j.febslet.2003.09.001

Liu, R., Xu, B., Zhou, X., Jia, B., and Cen, Y. (2019). Mitochondrial DNA-induced apoptosis and phenotypic changes and death. J. Hepatol. 726. doi:10.1053/j.hep.2019.07.008

Nguyen, K. D., Sundaram, V., and Aroyo, W. S. (2014). Atypical causes of cholestasis. World J. Gastroenterol. 20 (28), 9418–9426. doi:10.3748/wjg.v20.i28.9418

Nicotera, P., McConeky, D., Svensson, S. A., Bellomo, G., and Orrenius, S. (1988). Correlation between cytosolic Ca2+ concentration and cytotoxicity in hepatocytes exposed to oxidative stress. Toxicology 52 (1–2), 55–63. doi:10.1016/0300-4888(88)90196-5

Nissanka, N., and Moraes, C. T. (2018). Mitochondrial DNA damage and reactive oxygen species in neurodegenerative disease. FEBS Lett. 592 (5), 728–742. doi:10.1002/1873-3468.12956

Oliva-Vilarino, N., Hankevich, S., Vorinick, S. U., Mikrshian, S. A., and Rauchmüller, M. (2019). Cyclosporine-induced endoplasmic reticulum stress triggers tubular phenotypic changes and death. Am. J. Transpl. 19 (11), 2283–2296. doi:10.1002/ajt.42039

Palomero, J., Galan, A. I., Munoz, M. E., Tunon, M. J., Gonzalez-Gallego, J., and Jimenez, R. (2001). Effects of aging on the susceptibility to the toxic effects of cyclosporine A in rats. Changes in liver glutathione and antioxidant enzymes. Free Radic. Biol. Med. 30 (8), 836–845. doi:10.1016/s0891-5849(01)00471-3

Paolini, C., Quarta, M., Wei-LaPierre, I., Michelucci, A., Nori, A., Raggiunni, C., et al. (2015). Oxidative stress, mitochondrial damage, and cicles in muscle from calloscotrin-1 knockout mice. Skelet. Muscle 5, 10. doi:10.1371/journal.pone.01393.015-0035-9

Pastore, A., Federici, G., Bertini, E., and Piemonte, F. (2003). Analysis of glutathione: Implication in redox and detoxification. Clin. Chem. Acta. 333 (1), 19–39. doi:10.1000998911(03)00200-6

Patocka, J., Nepovimova, E., Kuca, K., and Wu, W. (2021). Cyclosporine A: Chemotherapy and toxicity - a review. Curr. Med. Chem. 28 (20), 3925–3934. doi:10.2174/0929867334666201006153202

Peconrella, I., Giardi, A., Rahimi, S., Di Tondo, D., and Di Tondo, U. (1990). Cholestasis in liver transplantation: Incidence and diagnostic significance. Pathology 82 (1018), 513–518.

Peng, T. I., and Jou, M. J. (2010). Oxidative stress caused by mitochondrial calcium overload. Ann. N. Y. Acad. Sci. 1201, 183–188. doi:10.1111/j.1749-6632.2010.06534.x

Qin, H., Zhang, L. L., Xiong, S. L., Jiang, X. Z., Xiao, C. P., Zhang, L. L., et al. (2020). Li-Dan-He-J improves infantile cholestasis-hepatopathy through inhibiting calcium-sensing receptor-mediated hepatocyte apoptosis. Front. Pharmacol. 11, 156. doi:10.3389/fphar.2020.00156

Rehman, H., Ramkesh, V. K., Thenwarth, T. P., Kim, I., Currin, R. T., Giri, S., et al. (2000). NMDH1 (N-methyl-4-isoucine cyclosporine), a mitochondrial permeability transition inhibitor, attenuates cholestatic liver injury but not fibrosis in mice. J. Pharmacol. Exp. Ther. 317 (4), 699–706. doi:10.1124/jpet.2000.143578

Reichen, J., Berr, F., Le, M., and Warren, G. H. (1985). Correlation between cytosolic Ca2+ concentration and cytotoxicity in hepatocytes exposed to oxidative stress. J. Biol. Chem. 260 (33), 17780–17787. doi:10.1016/s0021-9258(17)34206-8

Reznik, R. (2004). Cyclosporine A and adverse effects on organs Histochecnal studies. Path. Histochem. Cytochem. 39, 22, 5.1–8. doi:10.2214/01/40001

Rodrigues-Diez, R., Gonzalez-Guerrero, C., Ocana-Salceda, C., Rodrigues-Diez, R. R., Egido, J., Ortiz, A., et al. (2016). Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation throughTLR4 signaling. Sci. Rep. 6, 29715. doi:10.1038/srep29715

Rolo, A. P., Oliveira, P. J., Moreno, A. J., and Palmeira, C. M. (2000). Bile acids affect liver mitochondrial bioenergetics. Possible relevance for cholestasis therapy. Toxicol. Sci. 57 (1), 177–185. doi:10.1093/toxsci/57.1.177

Salucco, M. D., Chauvet-Monges, A. M., Tillement, J. P., Albengres, E., Testa, B., Currup, P., et al. (1996). Trimetazidine reverses calcium accumulation and impairment of phosphorylation induced by cyclosporine A in isolated rat liver mitochondria. J. Pharmacol. Exp. Ther. 277 (1), 417–422.
cyclosporine A-induced cholestatic effects in hepaRG cells. Toxicol. Sci. et al. (2014). Different dose-dependent mechanisms are involved in early induced bile duct injury. Chem. Res. Toxicol. ijms18030574

in vitro cyclosporine A in murine J. Gastroenterol. possible involvement of endoplasmic reticulum stress in biliary epithelial autophagy 368 dental health in children with cholestasis. donor liver transplantation. et al. (2008). Hepatotoxicity caused by both tacrolimus and cyclosporine after living drugs differentiated in human liver slices. Apoptosis its consequent effects on murine cholestatic liver injury. Frontiers in Pharmacology frontiersin.org13

Skrtic, M., Sriskanthadevan, S., Jhas, B., Gebbia, M., Wang, X., Wang, Z., et al. (2016). Mitochondrial mitochondrial reactive oxygen species differentiated in human liver slices. Mol. Cancer Res. 14 (1), 255–243. doi:10.1159/000462586

Sokol, R. J., Dahl, R., Devereaux, M. W., Yerushalmi, B., Sokol, R. J. (2001). Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and promoters of reparative macrophages mediated by ROS to orchestrate liver repair. Nat. Commun. 10 (1), 1076. doi:10.1038/s41467-019-09046-8

Yerushalmi, B., Dahl, R., Devereaux, M. W., Gumprecht, E., and Sokol, R. J. (2001). Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition. Hepatology 33 (3), 616–626. doi:10.1001/jp.2002.22702

Zeeshan, H. M., Lee, G. H., Kim, H. R., and Chae, H. J. (2016). Endoplasmic reticulum stress and associated ROS. Int. J. Mol. Sci. 17 (3), 327. doi:10.3390/ijms17030327

Zhang, T., Guo, J., Gu, J., Chen, K., Li, H., and Wang, J. (2019). Protective role of mTOR in liver ischemia/reperfusion injury: Involvement of inflammation and autophagy. Oxid. Med. Cell. Longev. 2019, 7861290. doi:10.1155/2019/7861290

Zhao, M., Wang, Y., Li, L., Liu, S., Wang, C., Yuan, Y., et al. (2021). Mitochondrial DNA in liver injury of patients with extrahepatic cholestasis: The protective effects of mitochondrial transcription factor A. Free Radic. Biol. Med. 52 (9), 1543–1551. doi:10.1016/j.freeradbiomed.2012.01.007

Yakim, K., Celen, S., Zhumatayev, S., Daloglu, H., Pahsayer, D., Ozturkmen, S., et al. (2021). Analyzing the clinical outcomes of switching from cyclosporine to tacrolimus in pediatric hematopoietic stem cell transplantation. Clin. Transpl. 35 (7), e4328. doi:10.1111/citr.14328

Yang, W., Tao, Y., Wu, Y., Zhao, X., Ye, W., Zhao, D., et al. (2019). Neutrophils promote the development of reparative macrophages mediated by ROS to orchestrate liver repair. Nat. Commun. 10 (1), 1076. doi:10.1038/s41467-019-09046-8

Yerushalmi, B., Dahl, R., Devereaux, M. W., Gumprecht, E., and Sokol, R. J. (2001). Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition. Hepatology 33 (3), 616–626. doi:10.1001/jp.2002.22702

Zeeshan, H. M., Lee, G. H., Kim, H. R., and Chae, H. J. (2016). Endoplasmic reticulum stress and associated ROS. Int. J. Mol. Sci. 17 (3), 327. doi:10.3390/ijms17030327

Zhang, T., Guo, J., Gu, J., Chen, K., Li, H., and Wang, J. (2019). Protective role of mTOR in liver ischemia/reperfusion injury: Involvement of inflammation and autophagy. Oxid. Med. Cell. Longev. 2019, 7861290. doi:10.1155/2019/7861290

Zhao, M., Wang, Y., Li, L., Liu, S., Wang, C., Yuan, Y., et al. (2021). Mitochondrial ROS promote mitochondrial dysfunction and inflammation in ischemic acute kidney injury by disrupting TPAM-mediated mtDNA maintenance. Theranostics 11 (4), 1845–1863. doi:10.7150/thno.59095

Zhou, A. Y., and Ryoe, S. (2014). Cyclosporin A promotes tumor angiogenesis in a calcium-unindependent manner by increasing mitochondrial reactive oxygen species. Mol. Cancer Res. 12 (11), 1663–1676. doi:10.1158/1541-7786.MCR-14-0136

Zhu, J., Dong, X., Liu, Q., Wu, C., Wang, Q., Long, Z., et al. (2016). Hydrophobic bile acids relax rat detrusor contraction via inhibiting the opening of the Na+/Ca2+ exchanger. Sci. Rep. 6, 21358. doi:10.1038/srep21358

Zu, Y., Wan, L. J., Cui, S. Y., Gong, Y. P., and Li, C. L. (2015). The mitochondrial Na+(Ca2+) exchanger may reduce high glucose-induced oxidative stress and nucleotide-binding oligomerization domain receptor 3 inflammasome activation in endothelial cells. J. Geriatr. Cardiol. 12 (3), 270–278. doi:10.1007/s11671-014-0303-3